2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Korman N, Warren R, Bagel J, Armstrong A, Gooderham M, Strober B, Thaçi D, Morita A, Imafuku S, Foley P, Sofen H, Zheng M, Hippeli L, Kisa R, Banerjee S, Blauvelt A. Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. Journal Of Dermatological Treatment 2024, 35: 2371045. PMID: 38945549, DOI: 10.1080/09546634.2024.2371045.Peer-Reviewed Original ResearchConceptsMaintenance of responseModerate to severe plaque psoriasisOnset of actionSevere plaque psoriasisPlaque psoriasisApremilast-treated patientsEfficacy measuresOral placeboClinical responseCoprimary endpointsDeucravacitinibPsoriasis trialsWeek 8PlaceboPASIPatientsWeek 1WeeksEfficacyPsoriasisSPGABaselineSignificant improvementTrialsApremilastDeucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Kisa R, Berger V, Vritzali E, Hoyt K, Colombo M, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s366. DOI: 10.25251/skin.8.supp.366.Peer-Reviewed Original ResearchModified nonresponder imputationPlaque psoriasisModerate to severe plaque psoriasisDiscontinuations due to AEsExposure-adjusted incidence ratesSevere plaque psoriasisParent trialAdverse cardiovascular eventsLong-term extensionTreatment of adultsSystemic therapyNonresponder imputationEfficacy outcomesHerpes zosterSafety profileVenous thromboembolismDeucravacitinibCardiovascular eventsEfficacy resultsPatientsResponse rateIncidence ratePsoriasisAllosteric TYK2 inhibitorEfficacy
2016
New Therapies for Psoriasis.
Strober B. New Therapies for Psoriasis. Seminars In Cutaneous Medicine And Surgery 2016, 35: s71-s73. PMID: 29850660, DOI: 10.12788/j.sder.2016.020.Peer-Reviewed Original ResearchAnti-interleukin-17 treatment of psoriasis
Jinna S, Strober B. Anti-interleukin-17 treatment of psoriasis. Journal Of Dermatological Treatment 2016, 27: 311-315. PMID: 26943806, DOI: 10.3109/09546634.2015.1115816.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisPlaque psoriasisTumor necrosis factor alphaIL-17 inhibitorsPhase 3 trialIL-17 receptor subunitNecrosis factor alphaEffective therapeutic targetIL-17Cytokine antagonistsInflammatory dermatosesIL-17RAFactor alphaSafety resultsTherapeutic targetPsoriasisFavorable responseUS populationReceptor subunitsMonoclonal antibodiesDependent pathwayTreatmentTrialsAntibodiesEfficacy
2014
Tumor necrosis factor inhibitors in psoriasis: an update.
Kerdel F, Strober B. Tumor necrosis factor inhibitors in psoriasis: an update. Seminars In Cutaneous Medicine And Surgery 2014, 33: s31-6. PMID: 24979543, DOI: 10.12788/j.sder.0066.Peer-Reviewed Original ResearchConceptsTumor necrosis factorTNF inhibitorsNecrosis factor inhibitorsTreatment of psoriasisCertolizumab pegolPlaque psoriasisPsoriatic arthritisFactor inhibitorsClinical trialsNecrosis factorPsoriasisRecent evidenceInhibitorsEfficacyGolimumabInfliximabPegolAdalimumabEtanerceptArthritisImmunogenicity
2005
Folate supplementation during methotrexate therapy for patients with psoriasis
Strober B, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. Journal Of The American Academy Of Dermatology 2005, 53: 652-659. PMID: 16198787, DOI: 10.1016/j.jaad.2005.06.036.Peer-Reviewed Original ResearchConceptsFolate supplementationSide effectsMethotrexate therapyFolinic acidFolic acidUse of methotrexateEfficacy of methotrexateIncidence of hepatotoxicityTreatment of psoriasisSignificant side effectsUse of folateGastrointestinal intoleranceFolate supplementsInflammatory conditionsMEDLINE searchClinical experiencePatientsMethotrexateFolate antagonistTherapySupplementationSearch termsPsoriasisEfficacyToxicity